Firefly Scientific has launched its OptiChallenge Inhibition Panel for use in evaluating the performance of an assay in the presence of interfering substances.
Interfering substances such as heparin, lipids, bilirubin and haemolysed plasma are found commonly in patient samples. At minimal levels, these substances do not interfere with assay results. However, when levels become elevated due to the effect of lifestyle or medications, these substances can hinder the amplification of nucleic acid assays. Studies show that 12.5% of incorrect and delayed test results affect patient health.
The OptiChallenge Inhibition Panel allows laboratories to identify limitations in testing due to the presence of interfering substances and enables appropriate actions to be taken.
www.fireflyscientific.co.uk